We are live on !
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
Turnover
44%
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter Est. Return
+14.65%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$331M
AUM Growth
+$11.7M
(+3.7%)
Cap. Flow
-$38.1M
Cap. Flow % of AUM
Cap. Flow %
-11.51%
Top 10 Holdings %
Top 10 Hldgs %
42.42%
Holding
75
New
12
Increased
16
Reduced
23
Closed
21
Avg Time Held
Equity + Options
0.7
years
Top 10 Avg Time Held
Equity + Options
0.2
years
Top 20 Avg Time Held
Equity + Options
0.4
years
Avg Time Held Equity only
0.8
years
Top 10 Avg Time Held Equity only
0.2
years
Top 20 Avg Time Held Equity only
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Novo Nordisk
NVO
|
+$14.7M |
| 2 |
Blueprint Medicines
BPMC
|
+$9.9M |
| 3 |
Sarepta Therapeutics
SRPT
|
+$8.99M |
| 4 |
Janux Therapeutics
JANX
|
+$6.09M |
| 5 |
Dyne Therapeutics
DYN
|
+$3.98M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biohaven
BHVN
|
+$19.1M |
| 2 |
Viridian Therapeutics
VRDN
|
+$8.38M |
| 3 |
MoonLake Immunotherapeutics
MLTX
|
+$8.04M |
| 4 |
Soleno Therapeutics
SLNO
|
+$7.18M |
| 5 |
Vaxcyte
PCVX
|
+$6.31M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.31% |
| 2 | Miscellaneous | 16.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Replimune Group
REPL
$1.04B
| $4.93M | 1.49% |
450,000
| – | – |
2023 Q4
3 quarters
|
|
27
PUT
Corbus Pharmaceuticals
CRBP
$86.3M
| $4.54M | 1.37% |
+220,000
| New | +$11.3M |
2024 Q3
0 quarters
|
|
28
BridgeBio Pharma
BBIO
$13.3B
| $4.46M | 1.35% |
175,000
+35,000
| +25% | +$919K |
2023 Q1
6 quarters
|
|
29
Taysha Gene Therapies
TSHA
$1.28B
| $4.32M | 1.31% |
2,150,000
+900,000
| +72% | +$1.97M |
2023 Q3
4 quarters
|
|
30
Rhythm Pharmaceuticals
RYTM
$6.07B
| $4.13M | 1.25% |
78,842
-38,546
| -33% | -$1.85M |
2024 Q1
2 quarters
|
|
31
Annexon
ANNX
$760M
| $3.85M | 1.16% |
650,000
+340,000
| +110% | +$2.02M |
2024 Q2
1 quarter
|
|
32
Korro Bio
KRRO
$131M
| $3.68M | 1.11% |
110,000
+10,000
| +10% | +$421K |
2024 Q2
1 quarter
|
|
33
CALL
Insmed
INSM
$20.8B
| $3.65M | 1.1% |
50,000
-150,000
| -75% | -$11.1M |
2024 Q2
1 quarter
|
|
|
34
Dyne Therapeutics
DYN
$2.84B
| $3.59M | 1.09% |
+100,000
| New | +$3.98M |
2024 Q3
0 quarters
|
|
35
Arvinas
ARVN
$475M
| $3.57M | 1.08% |
145,000
+70,000
| +93% | +$1.83M |
2023 Q4
3 quarters
|
|
|
36
Corbus Pharmaceuticals
CRBP
$86.3M
| $3.3M | 1% |
160,000
-15,000
| -9% | -$768K |
2024 Q1
2 quarters
|
|
37
BridgeBio Oncology
BBOT
$228M
| $3.13M | 0.95% |
300,000
| – | – |
2024 Q1
2 quarters
|
|
38
Nuvation Bio
NUVB
$1.57B
| $3.09M | 0.93% |
1,350,000
+200,000
| +17% | +$610K |
2024 Q2
1 quarter
|
|
39
Savara
SVRA
$951M
| $3.07M | 0.93% |
725,000
-325,876
| -31% | -$1.44M |
2023 Q4
3 quarters
|
|
40
Tenaya Therapeutics
TNYA
$84.7M
| $2.9M | 0.87% |
1,500,000
+150,000
| +11% | +$423K |
2024 Q1
2 quarters
|
|
41
Regenxbio
RGNX
$472M
| $2.78M | 0.84% |
265,000
+95,000
| +56% | +$1.16M |
2024 Q1
2 quarters
|
|
42
Corvus Pharmaceuticals
CRVS
$812M
| $2.64M | 0.8% |
+500,000
| New | +$1.8M |
2024 Q3
0 quarters
|
|
43
Absci
ABSI
$1.47B
| $2.1M | 0.63% |
+550,000
| New | +$2.19M |
2024 Q3
0 quarters
|
|
44
Neurogene
NGNE
$484M
| $2.1M | 0.63% |
50,000
-20,000
| -29% | -$776K |
2024 Q1
2 quarters
|
|
45
Capricor Therapeutics
CAPR
$387M
| $1.9M | 0.57% |
+125,000
| New | +$618K |
2024 Q3
0 quarters
|
|
46
DELISTED
Apellis Pharmaceuticals
APLS
| $1.87M | 0.57% |
65,000
-70,000
| -52% | -$2.59M |
2024 Q1
2 quarters
|
|
47
Summit Therapeutics
SMMT
$12.4B
| $1.86M | 0.56% |
+85,000
| New | +$1.19M |
2024 Q3
0 quarters
|
|
48
Spyre Therapeutics
SYRE
$7.92B
| $1.76M | 0.53% |
60,000
-190,237
| -76% | -$5.3M |
2024 Q1
2 quarters
|
|
|
49
Viridian Therapeutics
VRDN
$2.36B
| $1.71M | 0.52% |
75,000
-512,708
| -87% | -$8.38M |
2021 Q1
14 quarters
|
|
50
ProQR Therapeutics
PRQR
$185M
| $1.62M | 0.49% |
887,700
-12,300
| -1% | -$23.1K |
2024 Q2
1 quarter
|
|
Similar funds
SF
AFS
SFA
E
OHCM
MC
BRA
S
Ghost Tree Capital's Q3 2024 Portfolio in Review
As of Q3 2024, Ghost Tree Capital held 75 positions worth $331M, up 3.7% from $319M the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Ghost Tree Capital withdrew a net $38.1M in Q3 2024, closing 21 positions and reducing 23 holdings. Its most notable exit was Biohaven, an estimated $19.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 90% a quarter earlier, followed by Miscellaneous.
Against the trend, Ghost Tree Capital opened a new position in Novo Nordisk worth $13.1M.
- Ghost Tree Capital's largest Q3 2024 buy was Novo Nordisk: 110,000 shares worth $13.1M.
- Ghost Tree Capital added most to Blueprint Medicines in Q3 2024, an estimated $9.9M increase.
- Ghost Tree Capital's biggest Q3 2024 reduction was Viridian Therapeutics, cutting an estimated $8.38M.
- Ghost Tree Capital fully exited Biohaven in Q3 2024, selling an estimated $19.1M.
- Ghost Tree Capital's ten largest holdings make up 42% of its $331M portfolio in Q3 2024.
- Ghost Tree Capital opened 12 new positions and closed 21 in Q3 2024.
- Ghost Tree Capital's portfolio value rose 3.7% quarter-over-quarter to $331M.
Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.